Evidence map›Paper›PMID 37640885›Full record

ArticlePituitary2023

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers.

A Giustina, M M Uygur, S Frara, A Barkan, N R Biermasz, P Chanson, P Freda, M Gadelha, U B Kaiser, S Lamberts and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Pituitary, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Acromegaly complications: an update.The Journal of clinical endocrinology and metabolism · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. SAGITPituitary · 2025
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 10 countries.

A GiustinaInstitute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS Hospital, Via Olgettina 60, 20132, Milan, Italy. giustina.andrea@hsr.it.ORCID http://orcid.org/0000-0001-6783-3398
M M UygurInstitute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS Hospital, Via Olgettina 60, 20132, Milan, Italy.ORCID http://orcid.org/0000-0002-6569-8142
S FraraInstitute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS Hospital, Via Olgettina 60, 20132, Milan, Italy.ORCID http://orcid.org/0000-0002-1308-5598
A BarkanDivision of Endocrinology, University of Michigan Health System, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-5453-0248
N R BiermaszLeiden University Medical Center, Center for Endocrine Tumors Leiden, Leiden, The Netherlands.ORCID http://orcid.org/0000-0001-5817-3594
P ChansonUniversité Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, APHP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction et Centre de Référence des Maladies Rares de l'Hypophyse HYPO, Le Kremlin-Bicêtre, Paris, France.ORCID http://orcid.org/0000-0001-5096-5722
P FredaDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0002-1818-0762
M GadelhaInstituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0002-9250-3558
U B KaiserBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
S LambertsErasmus Medical Center, Rotterdam, The Netherlands.
E LawsPituitary/Neuroendocrine Center, Brigham & Women's Hospital, Boston, MA, USA.
L B NachtigallNeuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
V PopovicMedical Faculty, University of Belgrade, Belgrade, Serbia.
M ReinckeDepartment of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-9817-9875
C StrasburgerDepartment of Medicine for Endocrinology, Diabetes and Nutritional Medicine, Charité Universitätsmedizin, Berlin, Germany.
A J van der LelyPituitary Center Rotterdam, Endocrinology Section, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-1059-0126
J A H WassDepartment of Endocrinology, Churchill Hospital, University of Oxford, Oxford, United Kingdom.
S MelmedPituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2355-3447
F F CasanuevaDivision of Endocrinology, Santiago de Compostela University and Ciber OBN, Santiago, Spain.ORCID http://orcid.org/0000-0002-9052-8161
Vita-Salute San Raffaele University · ITBrigham and Women's Hospital · USErasmus MC · NLCedars-Sinai Medical Center · USCharité - Universitätsmedizin Berlin · DEChurchill Hospital · GBColumbia University · USHarvard University · USInserm · FRInstituto Estadual do Cérebro Paulo Niemeyer · BRLeiden University Medical Center · NLLMU Klinikum · DEUniversidade de Santiago de Compostela · ESUniversity of Belgrade · RSUniversity of Michigan · US

Funding

Pfizer 54333635
6 · The paper itself

Abstract

purposeThe Pituitary Society established the concept and mostly qualitative parameters for defining uniform criteria for Pituitary Tumor Centers of Excellence (PTCOEs) based on expert consensus. Aim of the study was to validate those previously proposed criteria through collection and evaluation of self-reported activity of several internationally-recognized tertiary pituitary centers, thereby transforming the qualitative 2017 definition into a validated quantitative one, which could serve as the basis for future objective PTCOE accreditation.

methodsAn ad hoc prepared database was distributed to nine Pituitary Centers chosen by the Project Scientific Committee and comprising Centers of worldwide repute, which agreed to provide activity information derived from registries related to the years 2018-2020 and completing the database within 60 days. The database, provided by each center and composed of Excel® spreadsheets with requested specific information on leading and supporting teams, was reviewed by two blinded referees and all 9 candidate centers satisfied the overall PTCOE definition, according to referees' evaluations. To obtain objective numerical criteria, median values for each activity/parameter were considered as the preferred PTCOE definition target, whereas the low limit of the range was selected as the acceptable target for each respective parameter.

resultsThree dedicated pituitary neurosurgeons are preferred, whereas one dedicated surgeon is acceptable. Moreover, 100 surgical procedures per center per year are preferred, while the results indicated that 50 surgeries per year are acceptable. Acute post-surgery complications, including mortality and readmission rates, should preferably be negligible or nonexistent, but acceptable criterion is a rate lower than 10% of patients with complications requiring readmission within 30 days after surgery. Four endocrinologists devoted to pituitary diseases are requested in a PTCOE and the total population of patients followed in a PTCOE should not be less than 850. It appears acceptable that at least one dedicated/expert in pituitary diseases is present in neuroradiology, pathology, and ophthalmology groups, whereas at least two expert radiation oncologists are needed.

conclusionThis is, to our knowledge, the first study to survey and evaluate the activity of a relevant number of high-volume centers in the pituitary field. This effort, internally validated by ad hoc reviewers, allowed for transformation of previously formulated theoretical criteria for the definition of a PTCOE to precise numerical definitions based on real-life evidence. The application of a derived synopsis of criteria could be used by independent bodies for accreditation of pituitary centers as PTCOEs.

Indexed as

Pituitary DiseasesPituitary NeoplasmsHumansPilot ProjectsPituitary GlandAcromegalyCenters of ExcellenceCriteriaCushing’s diseaseMedical treatmentNeurosurgeryPituitary tumorsProlactinoma

Identifiers

PMID37640885
PMCPMC10539196
OpenAlexW4386225424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.